NCT03787095: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 1 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03787095 |
|---|---|
| Title | Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: A Phase I/II, Double-blind, Placebo-controlled, Ascending Multiple Dose Study |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 13, 2019 |
| Completion date | Aug. 18, 2020 |
| Required reporting date | Aug. 18, 2021, midnight |
| Actual reporting date | Aug. 19, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 1 |